Rybelsus

Wegovy Pill vs Orforglipron: New Study Shows Superior Weight Loss and Tolerability

By Clinical Trials & Data Desk
2 April 2026

New clinical data reveals that oral semaglutide (Wegovy pill) offers greater weight loss efficacy and significantly better GI tolerability than orforglipron.

Tag: Rybelsus

Wegovy Pill vs Orforglipron: New Study Shows Superior Weight Loss and Tolerability

Areas Covered

Discover More

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN

LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C

GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline

Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement